This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q79.6 / Special Copayment Reduction: V155 / Re-approval cycle: 5 years |
| B. Synonyms | None (single entry) |
| C. Adult onset | Presents at various times from childhood to adulthood; the hypermobile type is often diagnosed in adulthood |
| 1. History | Described by Ehlers (1901) and Danlos (1908); Villefranche classification established in 1997 |
| 2. Causes | Abnormal synthesis and structure of collagen and connective tissue proteins; each of the 13 subtypes has different gene mutations |
| 3. Genetics | Inheritance pattern differs by subtype: autosomal dominant/recessive, X-linked recessive, etc. |
| 4. Epidemiology | Overall prevalence about 1/5,000; the hypermobile type is the most common |
| 5. Pathophysiology | Structural defects of connective tissue cause fragility of the skin, joints and blood vessels |
| 6. Symptoms | Skin hyperextensibility, joint hypermobility, chronic pain, autonomic dysfunction, etc. |
| 7. Signs | Gorlin sign, Beighton score, early scar formation, spheroids, etc. |
| 8. Screening | Beighton scoring system, family history investigation, skin biopsy |
| 9. Diagnosis | 2017 international classification criteria; subtype confirmed by molecular genetic testing |
| 10. Treatment | No curative treatment; physical therapy, pain management, surgical treatment for the vascular type |
| 11. Prognosis | Differs markedly by subtype; the vascular type is life-threatening |
| 12. Prevention | Fundamental prevention not possible; genetic counseling and prevention of complications are key |
| 13. References | Malfait F et al. The 2017 international classification of the Ehlers-Danlos syndromes. and 9 other papers |
The first clinical description of Ehlers-Danlos syndrome (EDS) dates back to the late 19th century. In 1891, the Russian dermatologist Tschernogubow first reported a patient with skin hyperextensibility and joint laxity, but formal academic naming began with a case report presented in Copenhagen in 1901 by the Danish dermatologist Edvard Lauritz Ehlers. Ehlers described clinical features such as skin hyperextensibility, joint laxity and scar formation after minor trauma. Subsequently, in 1908, the French dermatologist Henri-Alexandre Danlos presented a similar case, and the name 'Ehlers-Danlos syndrome', after the two researchers, was first used by Weber in 1936.
In the mid-20th century, discussion of subtype classification began in earnest. In 1967, Beighton and Horan proposed a quantitative assessment system for joint hypermobility, which later developed into the Beighton score. The 1986 Berlin classification divided EDS into 11 subtypes, but clinical and molecular criteria were mixed, causing problems with consistency. To overcome this, international experts met in Villefranche in 1997 and published the Villefranche classification, which reclassified EDS into 6 main subtypes (classical, hypermobility, vascular, kyphoscoliosis, arthrochalasia, dermatosparaxis). This classification integrated clinical diagnostic criteria and molecular genetic findings, improving diagnostic consistency.
With advances in molecular genetics, the etiology of individual subtypes began to be elucidated. COL3A1, the causative gene of vascular EDS, was identified by Pepin et al. in 1988, and subsequently COL5A1/COL5A2 mutations in the classical type, PLOD1 in the kyphoscoliotic type and others were revealed in turn. However, the causative gene of the hypermobile type (hEDS), which accounts for about 90% of all EDS patients, has still not been clearly identified as of 2025 and remains a focus of research. In 2017, the International EDS Association (IEDSC) formed a large multidisciplinary expert panel and published a new international classification, subdividing EDS into 13 subtypes and systematizing diagnostic criteria for each. This classification is currently used as the standard in clinical practice worldwide.
Ehlers-Danlos syndrome is a group of hereditary diseases caused by abnormalities in the synthesis, structure and processing of collagen and related proteins, the main components of connective tissue. Collagen is a key protein that maintains the structural integrity of connective tissue throughout the body, including the skin, tendons, ligaments, blood vessel walls and organ capsules, and the clinical phenotype differs depending on the step of its synthesis at which the defect occurs.
Classical EDS (cEDS) is caused by mutations in the COL5A1 or COL5A2 genes, which make up type V collagen, or rarely in the COL1A1 gene of type I collagen. Type V collagen is involved in fibril formation in the skin, and abnormalities of this protein cause impaired regulation of collagen fibril diameter and fragility of the skin and ligaments. Vascular EDS (vEDS) is caused by mutations in the COL3A1 gene, which encodes type III collagen; type III collagen plays a structural role in the connective tissue of blood vessel walls and internal organs. Defects in this gene markedly increase the risk of rupture of medium and large blood vessels and hollow organs.
Kyphoscoliotic EDS (kEDS) is caused by mutations in the PLOD1 gene, which encodes lysyl hydroxylase 1, or the FKBP14 gene, which encodes FKBP22. This enzyme is involved in post-translational modification of collagen, and in its deficiency collagen cross-linking does not form normally, reducing the mechanical strength of tissues. Arthrochalasia EDS (aEDS) is caused by tenascin-X deficiency due to TNXB gene mutations; tenascin-X coordinates the spatial arrangement of collagen fibrils in the extracellular matrix. In addition, dermatosparaxis EDS (dEDS) is caused by mutations in genes related to proteoglycan biosynthesis, such as B4GALT7, B3GALT6 and B3GAT3, and musculocontractural EDS (mcEDS) arises from mutations in the CHST14 or DSE genes. The causative gene of the most common subtype, hypermobile EDS (hEDS), has not yet been identified, and a combined action of polygenic or environmental factors is suggested.
Ehlers-Danlos syndrome shows various inheritance patterns depending on the subtype, including autosomal dominant, autosomal recessive and X-linked recessive. This genetic heterogeneity is a key consideration in the clinical classification of EDS and in genetic counseling.
Subtypes that follow autosomal dominant inheritance include classical (cEDS, COL5A1/COL5A2), classical-like (clEDS, some TNXB), hypermobile (hEDS, gene not identified), vascular (vEDS, COL3A1), some arthrochalasia, spondylodysplastic (spEDS, CHST6) and brittle cornea syndrome (BCS, ZNF469/PRDM5) types. In vascular EDS, new (de novo) mutations account for about 25–50% of all cases, so the diagnosis should not be excluded even when there is no family history.
Subtypes that follow autosomal recessive inheritance are kyphoscoliotic (kEDS, PLOD1/FKBP14), musculocontractural (mcEDS, CHST14/DSE), dermatosparaxis (dEDS, B4GALT7/B3GALT6/B3GAT3), osteodysplastic (BCS), some brittle cornea syndrome, temporomandibular joint type (TMJEDS) and myopathic (mEDS, COL12A1) types. Because inheritance is recessive, carrier parents have no or mild clinical symptoms, and the sibling recurrence rate is 25%.
For molecular genetic testing, next-generation sequencing (NGS) panels or whole-exome sequencing (WES) are mainly used. EDS panels including the known causative genes have a high diagnostic yield, but in hEDS molecular diagnosis has not been established and diagnosis relies on clinical criteria. For the COL3A1 gene, glycine substitution mutations (substitution of a glycine in the Gly-X-Y repeat sequence with another amino acid) are the most common, destabilizing the collagen triple-helix structure and making it vulnerable to proteolysis. Various other variant types, such as mRNA splicing abnormalities, frameshift variants and nonsense mutations, have also been reported. Genotype-phenotype correlations are partially established in some subtypes, but because variation in clinical severity is observed even within families carrying the same variant, complete phenotypic prediction remains difficult.
The overall prevalence of Ehlers-Danlos syndrome was previously estimated at about 1/5,000, but since the 2017 revision of the classification redefined the diagnostic criteria for the hypermobile type, estimates of actual prevalence have been controversial. According to a recent large survey by the Ehlers-Danlos Society in the UK, it has also been claimed that the overall prevalence of EDS including hEDS may reach about 1 per 1,000 population.
Looking at prevalence by subtype, the hypermobile type (hEDS) is the most common subtype, accounting for about 80–90% of all EDS, and is diagnosed more often in women (female:male = about 3–5:1). Whether this sex bias is a biological difference or a diagnostic bias is still debated. The prevalence of the classical type (cEDS) is estimated at about 1/20,000–1/40,000. The vascular type (vEDS) is relatively rare at about 1/50,000–1/200,000, but its clinical importance is very great because of the risk of life-threatening complications. The remaining subtypes, such as kyphoscoliotic and arthrochalasia, are rare disease groups with only hundreds to thousands of cases each reported worldwide.
Regionally, EDS occurs in all races and ethnic groups worldwide, but because of genetic bottleneck effects, the prevalence of some subtypes may be high in certain populations. By age, in hEDS and cEDS, symptoms often first appear from childhood to adolescence, but delayed diagnosis is common and many are first diagnosed in adulthood. In fact, the average time to diagnosis has been reported to reach about 10–20 years, so raising clinician awareness for early diagnosis is important. In Korea, systematic epidemiological data are lacking, but data are gradually accumulating through the rare disease registration system.
The pathophysiology of Ehlers-Danlos syndrome differs by subtype, but the common core is a structural and functional defect in components of the extracellular matrix (ECM). Connective tissue is a complex network composed of collagen, elastin, proteoglycans, glycoproteins and others that gives mechanical strength and elasticity to the skin, blood vessels and organs. When a defect arises in any one element of this network, the tensile strength, elasticity and wound-healing capacity of connective tissue decline overall.
In classical EDS, abnormalities of type V collagen make skin fibril formation abnormal. On electron microscopy, collagen fibrils of uneven diameter and the formation of "cauliflower"-shaped composite fibrils are characteristic. Type V collagen is normally located inside type I collagen fibrils and regulates fibril diameter, so its deficiency causes abnormal fusion of fibrils. In vascular EDS, the defect of type III collagen weakens the tunica media of blood vessels and the walls of hollow organs (uterus, colon, bladder, etc.). The abnormal collagen triple helix due to COL3A1 mutations exerts a dominant-negative effect, combining with normal collagen and weakening the entire fibril.
In kyphoscoliotic EDS, deficiency of lysyl hydroxylase 1 prevents formation of pyridinolinium cross-links, markedly reducing the tensile strength of collagen fibers. These cross-links are essential for maintaining mechanical stability particularly in musculoskeletal and ocular tissues. In arthrochalasia EDS, tenascin-X deficiency reduces the density of collagen fibrils in the skin and ligaments and decreases the elastic recoil of the extracellular matrix. In hypermobile EDS, the etiology is unclear because the causative gene has not been identified, but some studies suggest abnormalities of proteins of the small leucine-rich proteoglycan (SLRP) family or abnormal signaling at cytoskeleton–extracellular matrix junctions. As a mechanism of chronic pain, central and peripheral sensitization has been proposed to play an important role.
The symptoms of Ehlers-Danlos syndrome vary greatly by subtype and severity, and there is wide variation between individuals even within the same subtype. The main symptom groups common across all subtypes are as follows.
Musculoskeletal symptoms are the core symptoms of EDS, typified by joint hypermobility and the resulting recurrent dislocations and subluxations. Patients experience dislocations of the shoulder, knee, ankle and finger joints during daily activities or with minor trauma. Chronic joint and muscle pain is very common and seriously affects quality of life, especially in hEDS patients. Early joint degeneration may progress by adulthood. Among skin symptoms, skin hyperextensibility is characteristic: when pulled, the skin stretches abnormally but returns to its original position when released. A velvety or doughy skin texture is characteristic, and wound healing after minor trauma is poor, forming wide atrophic scars. Because of skin fragility, bruising occurs easily and subcutaneous hematomas are frequent.
Cardiovascular symptoms vary by subtype. In the hypermobile and classical types, postural orthostatic tachycardia syndrome (POTS) or autonomic dysfunction often coexists, and patients complain of palpitations, headache, dizziness and presyncope on standing. In vascular EDS, patients may be asymptomatic until a sudden arterial rupture or bowel perforation appears as the first symptom, which is particularly dangerous. Gastrointestinal symptoms commonly include bowel hypersensitivity, gastrointestinal motility disorders, gastroesophageal reflux, and constipation or diarrhea. Urinary symptoms reported include bladder dysfunction and pelvic floor dysfunction. Autonomic symptoms may include impaired temperature regulation, sweating disorders, dry mouth and dry eyes. In addition, fatigue and sleep disturbances are very common, and mental health problems such as anxiety and depression are also reported at significantly higher frequency in EDS patients than in the general population.
The clinical signs of Ehlers-Danlos syndrome can be identified through systematic physical examination and form the core of the diagnostic criteria. The main signs are as follows.
The Beighton score is a quantitative assessment tool for joint hypermobility, consisting of a 9-point system: extension of the little finger beyond 90° (1 point each side), flexion of the thumb to the forearm (1 point each side), elbow hyperextension beyond 10° (1 point each side), knee hyperextension beyond 10° (1 point each side), and palms placed fully flat on the floor on forward flexion with the knees straight (1 point). For hEDS, the 2017 classification sets the positive threshold at 5 or more points in adults, 6 or more in children and adolescents, and 4 or more in those aged 50 or older. However, a diagnosis should not be made by the Beighton score alone; it should be interpreted together with the overall clinical context.
The Gorlin sign is the ability to touch the tip of the nose with the tongue and is one of the phenotypes of hypermobility. Skin hyperextensibility is judged positive when the skin of the volar forearm stretches 3cm or more when pulled, and it is particularly marked in classical EDS. Atrophic scars are found in frequently injured areas such as the knees and anterior shins and reflect reduced tensile strength of the skin. Molluscoid pseudotumors are fatty cystic lesions that form at pressure points (e.g., elbows, knees). Spheroids are small calcified subcutaneous nodules, palpable especially on the forearms and over the tibia. Myofascial pain tender points are also often found. In vascular EDS, appearance features such as thin, translucent skin through which subcutaneous vessels are visible (translucent skin), aged facial features, thin helices of the ears and a short philtrum provide clues. Ocular signs such as eyelid hyperextensibility, blue sclerae and keratoconus are observed in some subtypes.
Although Ehlers-Danlos syndrome is a rare genetic disease, its diagnosis is often markedly delayed, so applying appropriate screening methods in clinical practice is important. Evaluation for screening purposes is centered on clinical examination, and no specific biochemical or imaging screening test exists.
As a key questionnaire for clinical screening, the five-part hypermobility questionnaire (5-PQ) is used: ① Is your skin soft and stretchy? ② Do you bruise more easily than others? ③ Do you frequently dislocate joints during exercise without braces? ④ Do you have widespread musculoskeletal pain (≥3 months)? ⑤ Does anyone in your family have overly flexible joints or hyperextensible skin? If 2 or more of these are positive, further evaluation is recommended. Beighton score measurement is the standard for screening joint hypermobility and can be performed easily even in primary care. However, because the Beighton score focuses on the large joints of the upper and lower limbs, it is recommended to supplement it with a generalized joint hypermobility assessment index (Generalized Joint Hypermobility score) that includes the spine, shoulders, hips, temporomandibular joints and others.
When vascular EDS is suspected, collagen analysis by skin biopsy may be performed selectively, but molecular genetic testing now takes priority. Family history investigation is a key part of screening, and a history in the family of unexplained vascular abnormalities, early death, recurrent dislocations and the like should be checked. In children with joint pain, growth delay or spinal abnormalities, EDS should be included in the differential diagnosis. Measurement of the lysyl pyridinoline (LP):hydroxylysyl pyridinoline (HP) ratio on urine testing is useful for screening for kyphoscoliotic EDS.
The diagnosis of Ehlers-Danlos syndrome is made according to the 2017 International Classification of the Ehlers-Danlos Syndromes, combining clinical criteria with molecular genetic confirmation. Diagnostic criteria and confirmation methods differ by subtype.
The diagnosis of hypermobile EDS (hEDS) relies purely on clinical criteria, and all three criteria must be met. Criterion 1: generalized joint hypermobility (meeting the age-specific Beighton score threshold). At least 2 of criteria 2A–2C met: 2A (5 of 5 signs, or 2 of 5 signs related to tissue fragility), 2B (positive family history), 2C (musculoskeletal complications—chronic pain or early dysfunction). Criterion 3: exclusion of other causes. hEDS is diagnosed after first excluding subtypes for which molecular diagnosis is possible, such as the classical and arthrochalasia types.
The diagnosis of vascular EDS (vEDS) combines clinical criteria (characteristic facial features, skin translucency, vascular/visceral complications, positive family history) with molecular genetic confirmation of COL3A1. When there are clinically suspicious findings, genetic testing should be performed immediately, and invasive procedures (including angiography) should be minimized because of vascular fragility. A biochemical method confirming reduced secretion of type III collagen in fibroblast cultures from a skin biopsy may also be used as a diagnostic aid, but molecular testing takes priority. Classical EDS (cEDS) is diagnosed by assessing the major criteria of skin hyperextensibility, atrophic scars and joint hypermobility and the minor criteria, with molecular confirmation of COL5A1/COL5A2. Kyphoscoliotic EDS (kEDS) is diagnosed with the major criteria of congenital hypotonia, early-onset kyphoscoliosis and joint laxity, together with the urinary LP:HP ratio (1 or more; normal less than 0.2) and molecular confirmation of PLOD1/FKBP14. When a variant of uncertain significance (VUS) is detected on any molecular test, segregation analysis through testing of parents and siblings and additional functional studies are performed to determine pathogenicity.
There is still no curative treatment for Ehlers-Danlos syndrome, and current treatment centers on a multidisciplinary approach focused on symptom relief, prevention of complications and maintenance of function.
Physical therapy and exercise therapy are the most important treatments for maintaining musculoskeletal function in hEDS and cEDS. Low-impact exercise that strengthens the muscles around joints to increase joint stability (swimming, Pilates, low-intensity resistance exercise) is recommended. Education in joint protection techniques and the use of orthotics and supports are helpful. However, excessive stretching and high-impact activities should be avoided. Pain management is a key challenge in patients with chronic pain, and a multimodal approach is needed that includes medications (NSAIDs, low-dose tricyclic antidepressants, duloxetine, pregabalin), non-drug treatments (cognitive behavioral therapy, mindfulness-based therapy) and nerve blocks. Long-term use of opioids should be decided carefully because of the risks of dependence and worsening central sensitization.
For autonomic dysfunction (POTS), increased fluid and salt intake, compression stockings and medications (midodrine, fludrocortisone, ivabradine, beta-blockers) are used. In vascular EDS, emergency surgical management is needed when arterial or visceral rupture occurs, but because tissue fragility makes the risk of surgical complications very high, collaboration with an experienced vascular surgery and critical care team is essential. Prophylactic vascular surgery is generally not recommended, but with accumulating recent clinical experience data, selective indications have been proposed. Celiprolol can be considered because a small randomized controlled trial showed that it reduces the frequency of vascular events in patients with vascular EDS. When there are ophthalmologic complications, regular ophthalmologic follow-up and corneal cross-linking treatment for keratoconus are performed. Mental health support, linkage to social welfare services, patient education and participation in self-help groups are also part of comprehensive treatment.
The prognosis of Ehlers-Danlos syndrome differs dramatically by subtype and, even within the same subtype, varies greatly depending on the presence and severity of complications. Therefore, confirming the subtype at the initial diagnosis of an EDS patient is essential for explaining prognosis and planning follow-up management.
Hypermobile EDS (hEDS) does not directly shorten life, but functional decline due to chronic pain, chronic fatigue and recurrent dislocations is severe and markedly lowers quality of life. Many patients are limited in occupational and social functioning by pain and fatigue, and the comorbidity rates of depression and anxiety disorders are high. Classical EDS (cEDS) involves functional decline from skin and joint complications, but with appropriate management and injury prevention a relatively normal life span can be expected. Poor scar formation after skin injury increases cosmetic problems and the risk of skin infection.
Vascular EDS (vEDS) is the subtype with the most serious prognosis, with a median survival age reported at about 48–50 years. About 25% of all cases experience a major vascular complication before age 40, including rupture of the aorta, celiac artery, mesenteric arteries and others, or colonic perforation. Mortality after the first major vascular complication is high. In pregnant women the risk of uterine rupture is high, so special attention is needed in obstetric management. Kyphoscoliotic EDS (kEDS) carries risks of cardiopulmonary compromise due to progressive kyphoscoliosis and of blindness due to retinal detachment and corneal rupture. Dermatosparaxis EDS (dEDS) has a complex prognosis due to multiple organ abnormalities such as intellectual disability, growth delay and joint contractures. In all subtypes, early diagnosis, multidisciplinary follow-up and education on complication prevention contribute to improved prognosis.
Because Ehlers-Danlos syndrome is a hereditary disease, preventing its onset is not possible with current technology. However, prevention of complications, timely treatment through early diagnosis and family planning through genetic counseling are the most important preventive strategies.
Prevention of complications requires tailored lifestyle guidance that takes subtype characteristics into account. To protect joints, high-impact sports (soccer, basketball, running, etc.) should be avoided, and low-impact aerobic exercise such as swimming, cycling and water aerobics is recommended. To prevent skin injury, sharp objects and activities with heavy friction should be avoided, and when wound closure is needed, suturing techniques that minimize skin tension should be used. In patients with vascular EDS, blood pressure control is important, and they are educated to avoid excessive physical activity, increased abdominal pressure, straining and the like. Prevention of constipation (dietary fiber intake, sufficient fluid intake) also contributes to preventing visceral complications. Women with vascular EDS planning pregnancy need thorough counseling on the risks of pregnancy, and a collaborative obstetric–cardiovascular surgery system should be established throughout pregnancy.
Genetic counseling must be provided to confirmed patients and their families. For autosomal dominant subtypes (hEDS, cEDS, vEDS, etc.), it is explained that children have a 50% risk of inheritance, and for autosomal recessive subtypes, carrier testing and the 25% risk of disease in children are discussed. Preimplantation genetic testing (PGT) and prenatal diagnosis may be presented as options in families in which the causative gene has been identified, but the decision should be made after full discussion of the medical and ethical aspects. Referral to medical institutions specializing in rare diseases and linkage with patient organizations are also part of preventive management. In the long term, research on curative treatments such as gene therapy and collagen replacement therapy is under way, and identification of the causative gene of hEDS in particular remains a key task for drug development.